Detail Information of Mutation-induced Spatial Variation
General Information of Drug Transporter (DT) | |||||
---|---|---|---|---|---|
DT ID | DTD0060 Transporter Info | ||||
Gene Name | ABCC7 | ||||
Transporter Name | Cystic fibrosis transmembrane conductance regulator | ||||
Gene ID | |||||
UniProt ID | |||||
Mutation-induced Structural Variation (MSV) of This DT | |||||
PDB ID | |||||
Expression System | Homo sapiens | ||||
Method | EM | ||||
Resolution | 3.2 Å | ||||
Corresponding chain | A | ||||
Mutation Site(s) | E1371Q | [1] | |||
Structure Details | |||||
Modeling Method | EM | ||||
Publication year | 2019 | ||||
PDB ID | Scanning Method | Resolution | Mutation Sites | Details | Ref |
1XMI | X-ray | 2.25 Å | F42S; F121A; H280R | [2] | |
Structure | |||||
Expression System | Escherichia coli | ||||
Corresponding chain | A/B/C/D/E | ||||
Sequence Length | 389-678 | Mutation | Yes | ||
1XMJ | X-ray | 2.3 Å | F22L; F42S; F46L; S162E; G164Q; A167K; L279R | [2] | |
Structure | |||||
Expression System | Escherichia coli | ||||
Corresponding chain | A | ||||
Sequence Length | 389-677 | Mutation | Yes | ||
2BBO | X-ray | 2.55 Å | F22L; F42S; F46L; S162E; G164Q; A167K; L279R | [3] | |
Structure | |||||
Expression System | Escherichia coli | ||||
Corresponding chain | A | ||||
Sequence Length | 389-678 | Mutation | Yes | ||
2BBS | X-ray | 2.05 Å | F42S; F107N; Q165R | [3] | |
Structure | |||||
Expression System | Escherichia coli | ||||
Corresponding chain | A/B | ||||
Sequence Length | 389-677 | Mutation | Yes | ||
2BBT | X-ray | 2.3 Å | F107N; L245R | [3] | |
Structure | |||||
Expression System | Escherichia coli | ||||
Corresponding chain | A/B | ||||
Sequence Length | 389-678 | Mutation | Yes | ||
2PZE | X-ray | 1.7 Å | T53M | [4] | |
Structure | |||||
Expression System | Escherichia coli | ||||
Corresponding chain | A/B | ||||
Sequence Length | 387-646 | Mutation | Yes | ||
2PZF | X-ray | 2 Å | T53M | [4] | |
Structure | |||||
Expression System | Escherichia coli BL21(DE3) | ||||
Corresponding chain | A/B | ||||
Sequence Length | 387-646 | Mutation | Yes | ||
2PZG | X-ray | 1.8 Å | T65M | [4] | |
Structure | |||||
Expression System | Escherichia coli | ||||
Corresponding chain | A/B | ||||
Sequence Length | 375-646 | Mutation | Yes | ||
References | |||||
1 | Structural identification of a hotspot on CFTR for potentiation. Science. 2019 Jun 21;364(6446):1184-1188. | ||||
2 | Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. J Biol Chem. 2005 Jan 14;280(2):1346-53. | ||||
3 | Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry. J Mol Biol. 2010 Feb 19;396(2):406-30. | ||||
4 | Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant. Protein Eng Des Sel. 2010 May;23(5):375-84. | ||||
5 | Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy. Protein Sci. 2016 Feb;25(2):360-73. | ||||
6 | Ligand binding to a remote site thermodynamically corrects the F508del mutation in the human cystic fibrosis transmembrane conductance regulator. J Biol Chem. 2018 Nov 16;293(46):17685-17704. | ||||
7 | Molecular structure of the ATP-bound, phosphorylated human CFTR. Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):12757-12762. | ||||
8 | Domain-interface dynamics of CFTR revealed by stabilizing nanobodies. Nat Commun. 2019 Jun 14;10(1):2636. | ||||
9 | RCSB PDB: Crystal structure of human NBD2 complexed with N6-Phenylethyl-ATP (P-ATP) | ||||
10 | RCSB PDB: Thermodynamic correction of F508del-CFTR by ligand binding to a remote site in the mutated domain | ||||
11 | RCSB PDB: Thermodynamic correction of F508del-CFTR by ligand binding to a remote site in the mutated domain | ||||
12 | RCSB PDB: Thermodynamic correction of F508del-CFTR by ligand binding to a remote site in the mutated domain | ||||
13 | RCSB PDB: Thermodynamic correction of F508del-CFTR by ligand binding to a remote site in the mutated domain | ||||
14 | RCSB PDB: Thermodynamic correction of F508del-CFTR by ligand binding to a remote site in the mutated domain | ||||
15 | RCSB PDB: Thermodynamic correction of F508del-CFTR by ligand binding to a remote site in the mutated domain | ||||
16 | RCSB PDB: Thermodynamic correction of F508del-CFTR by ligand binding to a remote site in the mutated domain | ||||
17 | RCSB PDB: Thermodynamic correction of F508del-CFTR by ligand binding to a remote site in the mutated domain | ||||
18 | RCSB PDB: Thermodynamic correction of F508del-CFTR by ligand binding to a remote site in the mutated domain | ||||
19 | RCSB PDB: Thermodynamic correction of F508del-CFTR by ligand binding to a remote site in the mutated domain | ||||
20 | RCSB PDB: A thermodynamically stabilized form of the second nucleotide binding domain from human CFTR shows a catalytically inactive conformation | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.